This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Pilot Study of the Neural Correlates of Treatment Effect on Nicotine Craving

This study has been completed.
Information provided by (Responsible Party):
Karen Drexler, Emory University Identifier:
First received: September 13, 2005
Last updated: June 13, 2014
Last verified: June 2014
The purpose of this study is to gather pilot data to determine feasibility of and guide the development of a larger clinical trial investigating the effects of topiramate as an adjunct to nicotine replacement therapy and behavioral counseling in smoking cessation treatment. It is hypothesized that topiramate will decrease nicotine craving and result in improved outcomes for smoking cessation.

Condition Intervention Phase
Tobacco Use Disorder Drug: Topiramate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Official Title: Nicotine Craving: Neural Correlates of Treatment Effect - A Pilot Study

Resource links provided by NLM:

Further study details as provided by Karen Drexler, Emory University:

Study Start Date: December 2004
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male

Inclusion Criteria:

  • Male, between ages of 18-55
  • Meets DSM-IV criteria for nicotine dependence
  • Smoke at least 20 cigarettes per day
  • Motivated to quit smoking

Exclusion Criteria:

  • Serious or unstable medical conditions
  • Current psychiatric disorder requiring medication or treatment
  • Taking medication that create risk of interaction with study drug
  • Current participation in another smoking cessation treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00208858

United States, Georgia
Atlanta VA Medical Center
Decatur, Georgia, United States, 30033
Sponsors and Collaborators
Emory University
Principal Investigator: Karen Drexler, MD Emory University, Atlanta VA Medical Center
  More Information

Responsible Party: Karen Drexler, Asc Professor/Director, Substance Abuse Treatment, Emory University Identifier: NCT00208858     History of Changes
Other Study ID Numbers: 0624-2004
DA00366-02 ( Other Identifier: Other )
TPN-100 ( Other Identifier: Other )
Study First Received: September 13, 2005
Last Updated: June 13, 2014

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Protective Agents
Anti-Obesity Agents processed this record on June 22, 2017